A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma
The purpose of this study is to assess the efficacy and safety of apatinib plus concurrent neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
COMBINATION_PRODUCT: Apatinib,Paclitaxel,Cisplatin,RT
The pathological complete response rate(pCR), The lesion disappeared completely by pathology, within 3 weeks after surgery
R0-resection rate, There was no residual by the microscope, within 3 weeks after surgery|Disease-free survival(DFS), Baseline to measured date of recurrence or death from any cause, 3 years|Overall survival (OS), Baseline to measured date of death from any cause, 1year|Adverse events Toxicity, Adverse events Toxicity according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.The number of Participants with adverse events will be recorded at each treatment visit., 3 years
The purpose of this study is to assess the efficacy and safety of apatinib plus concurrent neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma.